Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Aug 6

PMID 32752186

Citations 13

Authors

Kento Fujii

Yasuko Yamamoto

Yoko Mizutani

Kuniaki Saito

Mariko Seishima

Affiliations

Soon will be listed here.

Abstract

() is an enzyme known to suppress immune responses, and several reports have showed that it is associated with psoriasis. is an isoform of , recently identified as a catalytic enzyme in the tryptophan-kynurenine pathway, which is expressed in dendritic cells and monocytes. The expression of in immune cells suggests that may contribute to immune functions. However, the role of in the pathogenesis of psoriasis remains unclear. In this study, to elucidate the role of in psoriasis, we assessed imiquimod (IMQ)-induced psoriasis-like dermatitis in knockout (KO) mice. Skin inflammation, evaluated by scoring erythema, scaling, and ear thickness, was significantly worse in the KO mice than in the wild-type (WT) mice. The mRNA expression levels of TNF-α, IL-23p19, and IL-17A, key cytokines involved in the development of psoriasis, were also increased in the KO mice. Furthermore, immunohistochemistry revealed that the number of Ki67-positive cells in the epidermis and CD4-, CD8-, and IL-17-positive lymphocytes infiltrating the dermis were significantly increased in the KO mice. These results suggest that might decrease IL-17 expression, thereby resulting in the suppression of skin inflammation in IMQ-induced psoriasis-like dermatitis.

Citing Articles

Unraveling the gut-skin axis in atopic dermatitis: exploiting insights for therapeutic strategies.

Rios-Carlos M, Cervantes-Garcia D, Cordova-Davalos L, Bermudez-Humaran L, Salinas E Gut Microbes. 2024; 16(1):2430420.

PMID: 39601281 PMC: 11610564. DOI: 10.1080/19490976.2024.2430420.

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2).

Suvieri C, Belladonna M, Volpi C Cells. 2024; 13(22).

PMID: 39594642 PMC: 11593294. DOI: 10.3390/cells13221894.

Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function.

Suvieri C, De Marchis F, Mandarano M, Ambrosino S, Rossini S, Mondanelli G Int J Mol Sci. 2023; 24(22).

PMID: 38003426 PMC: 10671178. DOI: 10.3390/ijms242216236.

Kynurenine Pathway in Psoriasis-a Promising Link?.

Stepaniuk A, Baran A, Flisiak I Dermatol Ther (Heidelb). 2023; 13(8):1617-1627.

PMID: 37326759 PMC: 10366053. DOI: 10.1007/s13555-023-00958-4.

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.

Wu C, Spector S, Theodoropoulos G, Nguyen D, Kim E, Garcia A Cancer Metab. 2023; 11(1):7.

PMID: 37226257 PMC: 10207715. DOI: 10.1186/s40170-023-00307-1.

References

Elizei S, Poormasjedi-Meibod M, Wang X, Kheirandish M, Ghahary A . Kynurenic acid downregulates IL-17/1L-23 axis in vitro. Mol Cell Biochem. 2017; 431(1-2):55-65. DOI: 10.1007/s11010-017-2975-3. View

Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D . Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?. Am J Pathol. 2007; 171(6):1936-43. PMC: 2111116. DOI: 10.2353/ajpath.2007.070281. View

Ball H, Sanchez-Perez A, Weiser S, Austin C, Astelbauer F, Miu J . Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007; 396(1):203-13. DOI: 10.1016/j.gene.2007.04.010. View

Moos S, Mohebiany A, Waisman A, Kurschus F . Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. J Invest Dermatol. 2019; 139(5):1110-1117. DOI: 10.1016/j.jid.2019.01.006. View

Sano S, Chan K, Carbajal S, Clifford J, Peavey M, Kiguchi K . Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2004; 11(1):43-9. DOI: 10.1038/nm1162. View

Flutter B, Nestle F . TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013; 43(12):3138-46. DOI: 10.1002/eji.201343801. View

Fanti P, Dika E, Vaccari S, Miscial C, Varotti C . Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol. 2006; 45(12):1464-5. DOI: 10.1111/j.1365-4632.2006.02980.x. View

Mezrich J, Fechner J, Zhang X, Johnson B, Burlingham W, Bradfield C . An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010; 185(6):3190-8. PMC: 2952546. DOI: 10.4049/jimmunol.0903670. View

Wu J, Siller G, Strutton G . Psoriasis induced by topical imiquimod. Australas J Dermatol. 2004; 45(1):47-50. DOI: 10.1111/j.1440-0960.2004.00030.x. View

10.

Lebwohl M, Dinehart S, Whiting D, Lee P, Tawfik N, Jorizzo J . Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004; 50(5):714-21. DOI: 10.1016/j.jaad.2003.12.010. View

11.

Metz R, Smith C, DuHadaway J, Chandler P, Baban B, Merlo L . IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol. 2014; 26(7):357-67. PMC: 4432394. DOI: 10.1093/intimm/dxt073. View

12.

Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004; 50(5):722-33. DOI: 10.1016/j.jaad.2003.11.066. View

13.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

14.

El Malki K, Karbach S, Huppert J, Zayoud M, Reissig S, Schuler R . An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol. 2012; 133(2):441-51. DOI: 10.1038/jid.2012.318. View

15.

Fatokun A, Hunt N, Ball H . Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids. 2013; 45(6):1319-29. DOI: 10.1007/s00726-013-1602-1. View

16.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

17.

Greaves M, Weinstein G . Treatment of psoriasis. N Engl J Med. 1995; 332(9):581-8. DOI: 10.1056/NEJM199503023320907. View

18.

Hawkes J, Yan B, Chan T, Krueger J . Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018; 201(6):1605-1613. PMC: 6129988. DOI: 10.4049/jimmunol.1800013. View

19.

Ball H, Yuasa H, Austin C, Weiser S, Hunt N . Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol. 2008; 41(3):467-71. DOI: 10.1016/j.biocel.2008.01.005. View

20.

Yuasa H, Hasegawa T, Nakamura T, Suzuki T . Bacterial expression and characterization of molluscan IDO-like myoglobin. Comp Biochem Physiol B Biochem Mol Biol. 2007; 146(4):461-9. DOI: 10.1016/j.cbpb.2006.11.028. View